Pacira BioSciences (PCRX)

The company’s best-known product is EXPAREL, a liposomal formulation of bupivacaine designed to provide extended local analgesia following surgical procedures. EXPAREL is used by clinicians as part of multimodal pain-control protocols, where local anesthetics, anti-inflammatory medicines, and other approaches are combined to manage pain while limiting opioid exposure.

Pacira also markets ZILRETTA, an extended-release corticosteroid injection for pain associated with osteoarthritis of the knee. The product is administered directly into the joint and is aimed at patients seeking longer-lasting relief than conventional short-acting steroid injections may provide. Another commercial offering, iovera, is a handheld cryoanalgesia device that applies controlled cold to targeted nerves to deliver drug-free pain relief.

Beyond its marketed portfolio, Pacira invests in development programs that extend its focus on osteoarthritis and localized pain. These include PCRX-201, also known as enekinragene inzadenovec, a gene therapy candidate being evaluated for knee osteoarthritis. The company’s strategy centers on broadening adoption of non-opioid interventions across surgical and chronic pain settings while navigating the clinical, reimbursement, and competitive dynamics of the U.S. pain-management market.